Ciechanover Brings Proven Approach to Help Entrepreneurs Build Transformational Life Science Companies
MENLO PARK, CA — May 20, 2010 – Kleiner Perkins Caufield & Byers (KPCB), the Silicon Valley venture capital firm behind Genentech, today announced that Isaac Ciechanover (pronounced “sea-hanover”), M.D., has joined the firm as a Partner. He will provide counsel and guidance to the firm’s network of life science entrepreneurs.
For more than 15 years, Ciechanover has worked with entrepreneurs to advance medicine through innovation and technology. Ciechanover most recently served as the executive director of business development at Celgene Corporation where he spearheaded the company’s venture capital efforts that led to investments in Cylene Pharmaceuticals, PTC Therapeutics, GlobeImmune and Burrill Life Sciences Capital Fund. He led global teams for in-licensing, and merger and acquisition transactions with Array BioPharma, Agios Pharmaceuticals and Merck KGaA, among many others. He was also the global project leader for Celgene’s first clinical stage biologic therapy and initiated Celgene’s clinical and commercial alliance management activities.
“KPCB has a history of supporting cutting-edge advancements in the life sciences and is known as a highly strategic resource for entrepreneurs, medical professionals and scientists. I look forward to working with a group of professionals I’ve long respected,” said Ciechanover. “I am eager to begin supporting entrepreneurs and companies that can change the face of medicine.”
Before Celgene, Ciechanover managed business development and planning for Amylin Pharmaceuticals. Prior to Amylin, he drove life sciences venture capital efforts for Pequot Ventures, and earlier analyzed and vetted acquisition candidates at Pfizer Inc.
“Isaac is a great addition to the life science team at KPCB. His experience in business development at Celgene, one of the most successful biotech companies, in addition to his medical knowledge and business training, will be a great complement to our existing team,” said KPCB Partner Beth Seidenberg, M.D.
Ciechanover has always been interested in the business side of medicine and is excited by the potential to help a far larger number of people than he could as a physician. Having performed primary research in prenatal screening for cystic fibrosis, he is especially passionate about working with pediatric populations.
With both a medical and business background, Ciechanover bridges the gap between the scientific and business communities. Ciechanover has an MBA from Harvard Business School, an MD from Weill Cornell University Medical College, a master’s degree in Epidemiology from the University of Cambridge and a bachelor’s degree in Psychology from Stanford University. Ciechanover is a contributor to the Multiple Myeloma Research Foundation and Project Smile.
KPCB has partnered with scientists and entrepreneurs to build more than 100 companies and their breakthrough products in medical devices, drugs, vaccines, personalized medicine, diagnostics, and healthcare IT and services. KPCB works shoulder to shoulder with teams in their portfolio companies to pioneer recombinant DNA, monoclonal antibodies, stem cell research, molecular diagnostics, implantable therapeutic devices, combinatorial chemistry, non-viral vaccines, laser treatments and protein drug discovery.